Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Journal of Biological Sciences
Year: 2006  |  Volume: 6  |  Issue: 6  |  Page No.: 1053 - 1058

Comparative Immunogenicity of Commercially Available Recombinant Vaccines Against Hepatitis B in Human Urban Population of Bahawalpur District, Pakistan


Abstract: The immunogenicity profiles of the recombinant hepatitis B vaccines commercially available in Pakistan were compared to Engerix-B® in a double-blind, prospective equivalence study. A total of 744 subjects (449 male, 295 female) of different age group and professions (randomly selected) of urban areas of Bahawalpur district were included in this study. Population was divided in six different groups (children, young and adult of either sex) and each group was administered (intramuscularly) one brand of vaccine (0, 1 and 6 month schedule). Children groups were vaccinated by 10 μg while young and adults groups by 20 μg of respective vaccine. The participants had blood samples taken (3-times; at the time of second dose, one and six months after third dose). The seroprotection; geometric mean titer (mIU mL-1) of six different vaccine used, were found maximum 1880.46±12.48 with Amvax B and minimum 1790.62±18.26 with Hepa-B-vac in children group, from 1897.43±17.26 (Engirex-B) to 1815.46±12.74 (Hepa-B-vac) in young group and from 1881.75±10.97 (Amvax-B®) to 1729.82±8.85 (Hepa-B-vac) in adult group. The antibody titers <10 mIU mL-1 were found highest (3.8%) with Hepa-B-vac® and lowest (2.4%) with Amvax-B® and Hepavax-Gene®. Antibody titers 10<100, 100<1000 and >1000 mIU mL-1 were observed 14.56 (Hepa-B-vac®) to 9.1% (Amvax-B®), 40.56 (Heberbiovac) to 39.15% (Hepavax-Gene) and 48.8 (Engirex-B) to 41.61% (Hepa-B-vac), respectively. The study concluded that all the recombinant hepatitis B vaccines tested were equipotent and similar in immunogenicity to Engerix-B® in the human urban population of Bahawalpur-Pakistan.

Cited References   |    Fulltext    |   Related Articles   |   Back
  Related Articles

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility